GlucoTrack, Inc. (NASDAQ:GCTK) Sees Significant Growth in Short Interest

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totaling 96,610 shares, a growth of 287.2% from the August 31st total of 24,951 shares. Based on an average daily volume of 128,278 shares, the short-interest ratio is presently 0.8 days. Approximately 14.5% of the shares of the company are sold short.

Key Stories Impacting GlucoTrack

Here are the key news stories impacting GlucoTrack this week:

• Positive Sentiment: Lōkahi Therapeutics expanded its ai² PIPELINE™ program through a collaboration with Pepperdine E2B™. The partnership could support development of Lōkahi’s AI-driven asset platform and strengthen the subsidiary’s potential to generate fee-based revenue. Lōkahi Therapeutics expands ai2 Pipeline through collaboration with Pepperdine E2B
• Positive Sentiment: The earlier announcement that Lōkahi signed its first external, fee-for-service partnership triggered a major rally in GCTK shares. Investors viewed the agreement as an initial commercial validation of the ai² PIPELINE platform and Lōkahi’s strategy to turn internal development capabilities into a revenue-generating business. Why GlucoTrack shares traded higher
• Neutral Sentiment: Reported short interest rose sharply to 96,610 shares as of September 15, equal to about 14.5% of shares outstanding. This indicates elevated bearish positioning, but the short-interest ratio of less than one day also suggests limited days-to-cover risk. A separate report showing zero short interest appears inconsistent and may reflect a data error.
• Negative Sentiment: GlucoTrack priced a public offering expected to raise roughly $3 million, or approximately $3.1 million before expenses, at $2.04 per share. The financing provides cash for operations and development but creates dilution and was priced below levels reached during the Lōkahi-related rally, likely contributing to the recent decline. GlucoTrack prices public offering

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GCTK shares. Wall Street Zen raised GlucoTrack from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

GlucoTrack Stock Performance

Shares of GlucoTrack stock opened at $1.82 on Monday. The firm’s fifty day simple moving average is $4.54 and its 200-day simple moving average is $8.13. GlucoTrack has a 12 month low of $1.77 and a 12 month high of $136.29. The stock has a market capitalization of $1.29 million, a price-to-earnings ratio of -0.01 and a beta of 0.62. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.46 and a quick ratio of 0.46.

About GlucoTrack

GlucoTrack, Inc is a medical device company focused on developing glucose-monitoring technologies for people with diabetes. Its work is aimed at providing alternatives to conventional finger-stick testing and other invasive methods used to measure blood glucose.

The company’s earlier flagship product, GlucoTrack, was designed as a noninvasive glucose monitor that used a combination of ultrasonic, electromagnetic and thermal technologies to estimate glucose levels through the earlobe. GlucoTrack has also shifted its development focus toward an implantable continuous blood glucose monitoring system intended to provide ongoing glucose measurements over an extended period.

Historically known as Integrity Applications, Inc, the company adopted the GlucoTrack name to reflect its focus on glucose-monitoring technology.